Azenta Beats Revenue Estimates, Reports $0.21 EPS for Q4
Azenta, Inc. (NASDAQ:AZTA) announced its financial results for the fourth quarter ending September 30, 2025, on Nov. 21, 2025.
The company reported earnings per share of $0.21, matching analyst expectations. Revenue for the quarter reached $159.2 million, surpassing the estimated $156.4 million.
For the fourth quarter, Azenta's revenue increased 6% year-over-year, with 4% growth on an organic basis. Full fiscal year 2025 revenue grew 4%, driven by a 3% organic rise. The company also expanded its adjusted EBITDA margin by 310 basis points year-over-year.
Looking ahead to fiscal year 2026, Azenta anticipates organic revenue growth between 3% and 5%. It expects further adjusted EBITDA margin expansion of approximately 300 basis points.
Azenta maintains a strong liquidity position with a current ratio of approximately 2.96. Its debt-to-equity ratio stands at a low 0.03.
President and CEO John Marotta described fiscal 2025 as transformative, highlighting the 3% core revenue growth and significant margin expansion. Azenta expects to generate higher free cash flow in the coming year.
Azenta, Inc. (AZTA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.